Preview

Pediatric pharmacology

Advanced search

TOLERANCE OF CHILDREN OLDER THAN 4 YEARS TO ACELLULAR DPT-VACCINES: RESULTS OF A RETROSPECTIVE STUDY

https://doi.org/10.15690/pf.v13i6.1676

Abstract

Background. Pertussis is a highly contagious bacterial infection of airborne transmission type that still remains a serious problem in Russia and around the world. The only reliable means of specific prophylaxis of pertussis is vaccination. In Russia, only one revaccination from pertussis is provided at the age of one and a half years, which is done with whole-cell DTP vaccine, which is not used with children older than 4 years due to high reactogenicity. Imported acellular DTP vaccines are an alternative to whole-cell  vaccines licensed for use with older children.

Objective: Our aim was to study children’s tolerability of the vaccine containing acellular pertussis component.

Methods.  The safety of acellular DTP vaccines (DTaP, DTaP/IPV/Hib) has been analyzed in a retrospective  study with children older than 4 years at the department of vaccinal prevention of Scientific Center of Children’s Health (Moscow) in the period from December 2014  to December  2015.

Results.  The results of 123  vaccinated  children aged 4 to 9 have been studies. Among them, healthy children — 62, those having allergic disease — 30, those with other chronic diseases — 31. In the post-vaccination  period (3–7 days), local reactions (weak and/or strong) were recorded with 19 (31%) healthy children, 11 (37%) with children having allergic diseases, 9 (29%) with children having other chronic diseases. General reactions to vaccination (weak and/or strong) occurred with 11 (18%), 6 (20%), and 8 (26%) children respectively.

Conclusion. The compared groups did not differ in frequency of post-vaccination  reactions and their intensity, with the exception of strong local reactions that occurred more frequently with children having allergic diseases. 

About the Authors

A. G. Gaivoronskaya
Scientific Centre of Children Health
Russian Federation
Moscow


L. S. Namazova-Baranova
Scientific Centre of Children Health; Sechenov First Moscow State Medical University; N.I. Pirogov Russian National Research Medical University
Russian Federation


D. A. Novikova
Scientific Centre of Children Health
Russian Federation
Moscow


M. V. Fedoseenko
Scientific Centre of Children Health; Sechenov First Moscow State Medical University
Russian Federation


N. E. Tkachenko
Scientific Centre of Children Health
Russian Federation
Moscow


T. A. Kaljuzhnaya
Scientific Centre of Children Health
Russian Federation
Moscow


F. Ch. Shakhtakhtinskaya
Scientific Centre of Children Health
Russian Federation
Moscow


М. I. Broeva
Scientific Centre of Children Health; Sechenov First Moscow State Medical University
Russian Federation


References

1. Васюнина А.В., Краснова Е.И., Панасенко Л.М. Коклюш у детей // Лечащий врач. — 2011. — № 10 — С. 55–60. [Vasyunina AV, Krasnova EI, Panasenko LM. Koklyush u detei. Practitioner. 2011;(10):55–60. (In Russ).]

2. cdc.gov [Internet]. Centers for Disease Control and Prevention. Help Protect Babies from Whooping Cough. Content source: National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases [cited 2016 Dec 9]. Available from: http://www.cdc.gov/features/pertussis/.

3. Сиземов А.Н., Комелева Е.В. Коклюш: клиника, диагностика, лечение // Лечащий врач. — 2005. — № 7 — С. 82–87. [Sizemov AN, Komeleva EV. Koklyush: klinika, diagnostika, lechenie. Practitioner. 2005;(7):82–87. (In Russ).]

4. Федосеенко М.В., Галицкая М.Г., Гайворонская А.Г., Степанов А.А. Безопасность применения ацеллюлярной коклюшной вакцины у детей старше 4 лет // Медицинский вестник Северного Кавказа. — 2010. — Т. 19. — № 3. — С. 69–70. [Fedoseenko MV, Galitskaya MG, Gaivoronskaya AG, Stepanov AA. Bezopasnost’ primeneniya atsellyulyarnoi koklyushnoi vaktsiny u detei starshe 4 let. Medical news of North Caucasus. 2010;19(3):69–70. (In Russ).]

5. Инфекционная заболеваемость за 2015 год в РФ // Детские инфекции. — 2016. — Т. 15. — № 1 — С. 5. [Infektsionnaya zabolevaemost’ za 2015 god v RF. Detskie infektsii. 2016;15(1):5. (In Russ).]

6. Инфекционная заболеваемость в Российской Федерации за январь–сентябрь 2016 года. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. [Infektsionnaya zabolevaemost’ v Rossiiskoi Federatsii za yanvar’–sentyabr’ 2016 goda. Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka. (In Russ).] Доступно по: http://rospotrebnadzor.ru/activities/statisticalmaterials/statictic_details.php?ELEMENT_ID=7258. Ссылка активна на 12.12.2016.

7. Николаева И.В., Шайхиева Г.С. Коклюш на современном этапе // Вестник современной клинической медицины. — 2016. — Т. 9. — № 2 — С. 25–29. [Nicolaeva IV, Shaikhieva GS. Pertussis at the present stage. Bulletin of contemporary clinical medicine. 2016;9(2):25–29. (In Russ).] doi: 10.20969/VSKM.2016.9(2).25-29.

8. Письмо Роспотребнадзора РФ №01/2412-16-31 от 29.02.2016 «О разъяснении эпидемиологической целесообразности ревакцинации против коклюша». [Rospotrebnadzor Letter №01/2412-16-31 ot 29.02.2016 «O raz”yasnenii epidemiologicheskoi tselesoobraznosti revaktsinatsii protiv koklyusha». (In Russ).]

9. Федосеенко М.В., Галицкая М.Г., Ивардава М.И., и др. Коклюш возвращается? Усовершенствование борьбы с забытой детской инфекцией // Педиатрическая фармакология. — 2012. — Т. 9. — № 2 — С. 28–36. [Fedoseenko MV, Galitskaya MG, Ivardava MI, et al. Pertussis is coming back? Improvement of forgotten childhood infection control. Pediatric pharmacology. 2012;9(2):28–36. (In Russ).] doi: 10.15690/pf.v9i2.242.

10. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev. 2016;29(3):449–486. doi: 10.1128/CMR.00083-15.

11. WHO. Pertussis vaccines: WHO position paper August 2015. Wkly Epidemiol Rec. 2015;90(35):433–460.

12. Вакцины для профилактики коклюша (Позиция ВОЗ) // Педиатрическая фармакология. — 2008. — Т. 5. — № 1 — С. 91–94. [Vaccines for pertussis prevention (WHO position). Pediatric pharmacology. 2008;5(1):91–94. (In Russ).]

13. ecdc.europa.eu [Internet]. European Center for Disease Prevention and Control. Vaccine schedule. [cited 2016 Dec 9]. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.

14. Лакоткина Е.А., Харит С.М., Черняева Т.В., Брусов Н.К. Поствакцинальные осложнения (клиника, диагностика, лечение, профилактика). Пособие для практического врача. — СПб.; 2002. — 82 с. [Lakotkina EA, Kharit SM, Chernyaeva TV, Brusov NK. Postvaktsinal’nye oslozhneniya (klinika, diagnostika, lechenie, profilaktika). Posobie dlya prakticheskogo vracha. St. Petersburg; 2002. 82 p. (In Russ).]

15. Institute of medicine. Adverse events associated with childhood vaccine. Washihgton, DC: National academy press; 1994. 65 p.

16. Таточенко В.К., Озерецковский Н.А., Федоров А.М. Иммунопрофилактика-2014. Справочник. — М.: Педиатръ,; 2014. — 199 с. [Tatochenko VK, Ozeretskovskii NA, Fedorov AM. Immunoprofilaktika-2014. Spravochnik. 12 ed. Moscow: Pediatr”; 2014. 199 p. (In Russ).]

17. Плоткин С., Йоханнес Л., Мадхи Ш., Эстебан О. Вакцина АбКДС-ИПВ//PRP-T: обзор 16-летнего опыта клинического применения // Вопросы современной педиатрии. — 2012. — Т. 11. — № 1. — С. 18–36. [Plotkin SA, Liese J, Madhi S, Ortiz E. A DTAP–IPV//PRP~T vaccine: a review of 16 years’ clinical experience. Current pediatrics. 2012;11(1):18–36. (In Russ).] doi: 10.15690/vsp.v11i1.129.

18. Collins CL, Salt P, Carthy N, et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine. 2004;22(31–32):4262–4269. doi: 10.1016/j.vaccine.2004.04.027.

19. Langue J, Matisse N, Pacoret P, et al. Persistence of antibodies at 5–6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular pertussis at 5–6 years of age. Vaccine. 2004;22(11–12): 1406–1414. doi: 10.1016/j.vaccine.2003.10.026.

20. Рычкова О.А., Казакевич Н.В., Сенникова Н.П., Чемакина Д.С. Опыт применения комбинированной вакцины против дифтерии, коклюша, столбняка, полиомиелита и гемофильной инфекции типа у здоровых и детей с различными нарушениями здоровья // Педиатрическая фармакология. — 2011. — Т. 8. — № 4 — С. 76–81. [Rychkova OA, Kazakevich NV, Sennikova NP, Chemakina DS. The experience of a combined vaccine against diphtheria, pertussis, tetanus, polio and haemophilus influenzae type B in healthy children and children with various disabilities. Pediatric pharmacology. 2011;8(4):76–81. (In Russ).]

21. Харит С.М., Черняева Т.В., Начарова Е.П., и др. Ревакцинация детей в возрасте старше 1,5 лет против дифтерии, коклюша, столбняка, полиомиелита и гемофильной инфекции // Вопросы современной педиатрии. — 2009. — Т. 8. — № 6 — С. 20–25. [Kharit SM, Chernyaeva TV, Nacharova EP, et al. Re-vaccination of children over 1,5 years old against diphtheria, pertussis, tetanus, poliomyelitis and hemophilic infection. Current pediatrics. 2009;8(6):20–25. (In Russ).]


Review

For citations:


Gaivoronskaya A.G., Namazova-Baranova L.S., Novikova D.A., Fedoseenko M.V., Tkachenko N.E., Kaljuzhnaya T.A., Shakhtakhtinskaya F.Ch., Broeva М.I. TOLERANCE OF CHILDREN OLDER THAN 4 YEARS TO ACELLULAR DPT-VACCINES: RESULTS OF A RETROSPECTIVE STUDY. Pediatric pharmacology. 2016;13(6):601-606. (In Russ.) https://doi.org/10.15690/pf.v13i6.1676

Views: 909


ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)